Every SMA therapy the NHS funds reached routine commissioning through a conditional route first, and nusinersen and risdiplam took until 2026 to complete that transition.
The UK SMA precedent is a sequence, not a verdict. NICE recommended onasemnogene abeparvovec under HST15 in July 2021 for babies with a clinical diagnosis of type 1 SMA aged six months or under, or aged seven to twelve months with agreement from the national multidisciplinary team. In April 2023 NICE partially updated that guidance through HST24, extending the recommendation to presymptomatic babies aged twelve months and under. Neither appraisal was a rejection. The second widened the eligible population rather than reversing the first.
Nusinersen and risdiplam followed a slower path to the same destination. Both were funded through time-limited managed access agreements from 2019, while further evidence on their effectiveness was collected, and only under TA1162 did NICE recommend them for routine NHS commissioning, superseding TA588 and TA755. That sets the pricing question for a new UK entrant. The variable is not a single cost-per-QALY threshold to clear at launch. It is how long the asset sits under a conditional agreement, what evidence that agreement demands, and what price remains viable across that period. Our model prices the conditional and routine phases separately and sizes the evidence-collection commitment attached to each.
Every funded SMA therapy in England entered through a conditional route, and two of them took until TA1162 to leave it.
| Agent | NICE Route | Access Route | Where It Ended Up |
|---|---|---|---|
| Onasemnogene abeparvovec (Zolgensma, Novartis) | HST15 (Jul 2021), symptomatic type 1; HST24 (Apr 2023), presymptomatic | Highly Specialised Technologies route | Recommended at first appraisal, then extended to a second population by partial update |
| Nusinersen (Spinraza, Biogen) | TA588 (2019), superseded by TA1162 | Time-limited managed access from 2019 | Routine NHS commissioning under TA1162 |
| Risdiplam (Evrysdi, Roche) | TA755, superseded by TA1162 | Time-limited managed access from 2019 | Routine NHS commissioning under TA1162, alongside nusinersen |
| Novel SMA entrant | Target: shortest viable conditional period | Priced across conditional and routine phases | Modelled with the evidence-collection commitment costed into the revenue case |
Sources: NICE highly specialised technologies guidance HST15, onasemnogene abeparvovec for treating spinal muscular atrophy, published 7 July 2021 and partially updated April 2023; NICE HST24, onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy, April 2023; NICE TA1162, nusinersen and risdiplam for treating spinal muscular atrophy, superseding TA588 and TA755.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The eligible population under each appraisal, how the April 2023 partial update widened it, and what a second gene therapy submission has to engage with
Delivers
- The routes NICE has used in UK SMA, the evidence commitments each carries, and the revenue impact of the conditional period nusinersen and risdiplam served
Delivers
- The model's target WAC range by phase, the GTN waterfall by commissioning route, and how the model handles confidential commercial terms
Custom model delivered in 72 hours.
Assess this reportWhat's inside
- Why the length of the conditional period, not a single cost-per-QALY threshold, governs UK SMA pricing
- What the managed access route cost nusinersen and risdiplam in time to routine funding
- The HST and TA routes NICE has used in SMA and what each one demands
- Where a novel entrant should aim on that ladder
- What HST15 recommended in 2021 and for which infants
- How the April 2023 partial update extended eligibility to presymptomatic babies
- Nusinersen and risdiplam as the comparator set, from TA588 and TA755 through to TA1162
- What the analogue class supports for a new entrant's NICE case
- The WAC range the model produces across conditional and routine phases
- Where the evidence base is strong enough to support a premium
- The WAC-to-net waterfall decomposed by NHS commissioning route
- Why commercial terms agreed with NHS England are confidential and how the model handles that
- Sequencing recommendation for a gene therapy versus a chronic entrant
- Conservative, base, and aggressive revenue scenarios tied to NHS gene-therapy centre capacity
- The open pricing questions your team must close before a UK NICE submission is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary NICE and NHS sources, not secondary summaries. Findings are independently verified before inclusion.
SMA UK pricing sources: NICE HST15 (onasemnogene abeparvovec, 2021, partially updated 2023), NICE HST24 (presymptomatic SMA, 2023), and NICE TA1162 (nusinersen and risdiplam), which supersedes TA588 and TA755.
- HST15 and HST24 confirmed as two separate recommendations covering different populations, verified against the live NICE guidance record rather than characterised as a rejection followed by a reversal
- TA1162's supersession of TA588 and TA755, and the move from time-limited managed access to routine NHS commissioning, verified against NICE guidance
- No confidential commercial or patient access scheme net price is stated, because those terms are not published
Frequently asked questions
Commission this model
AXLRx delivers UK SMA pricing strategy models built for market access and pricing teams weighing a conditional NICE route against routine commissioning. Custom model in 72 hours.
Specify your indication, market basket, and comparator scope.
AXLRx analyst confirms pricing mechanism assumptions and WTP threshold before building.
Research-verified pricing model in 72 hours with optional analyst readout.